- Home
- UFCS vs TNDM Comparison
UFCS vs TNDM Comparison
Compare UFCS & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | TNDM |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | UFCS | TNDM |
|---|---|---|
| Price | $53.75 | $16.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 24 |
| Target Price | ★ $58.50 | $28.55 |
| AVG Volume (30 Days) | 108.5K | ★ 1.9M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $1,386,412,000.00 | $1,014,736,000.00 |
| Revenue This Year | $15.24 | $5.69 |
| Revenue Next Year | $19.13 | $12.35 |
| P/E Ratio | $21.79 | ★ N/A |
| Revenue Growth | ★ 10.62 | 7.93 |
| 52 Week Low | $29.85 | $12.26 |
| 52 Week High | $56.74 | $29.65 |
Technical Indicators
Market Signals| Indicator | UFCS | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 40.88 |
| Support Level | $51.75 | $14.44 |
| Resistance Level | $55.12 | $18.13 |
| Average True Range (ATR) | 1.46 | 1.05 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 26.04 | 54.69 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.